Prostate-specific antigen: A review of the validation of the most commonly used cancer biomarker

Javier Hernandez, Ian M. Thompson

Research output: Contribution to journalArticle

201 Citations (Scopus)

Abstract

BACKGROUND. The widespread use of prostate-specific antigen (PSA) screening has had a tremendous impact on all aspects of the management of prostate carcinoma. Although PSA-based screening has resulted in a stage migration to more organ-confined tumors at the time of diagnosis, and has been temporally associated with a decrease in prostate carcinoma mortality, PSA screening is imperfect. A recent analysis of results from the Prostate Cancer Prevention Trial (PCPT) has provided insight into the positive predictive value of PSA in the so-called "normal" range. METHODS. The history of the discovery, initial studies, and subsequent widespread application of PSA screening is reviewed. RESULTS. The application of PSA for screening preceded the development of current prostate biopsy techniques and an upper limit of normal was established without complete disease ascertainment. More recent modifications of PSA-based screening have been adopted clinically without sufficient validation. With current methods, overdiagnosis of clinically unimportant disease almost certainly occurs and high-grade, aggressive disease may not be detected sufficiently early to allow successful treatment. CONCLUSIONS. To the authors' knowledge, the optimal upper limit of normal for PSA for prostate carcinoma screening is unknown. New biomarkers of disease are needed; these must be linked with disease prognosis and must be validated in rigorously designed clinical trials.

Original languageEnglish (US)
Pages (from-to)894-904
Number of pages11
JournalCancer
Volume101
Issue number5
DOIs
StatePublished - Sep 1 2004

Fingerprint

Prostate-Specific Antigen
Tumor Biomarkers
Prostate
Carcinoma
Prostatic Neoplasms
Reference Values
Biomarkers
History
Clinical Trials
Biopsy
Mortality
Neoplasms

Keywords

  • Biomarkers
  • Prostate carcinoma
  • Prostate-specific antigen (PSA)
  • Screening

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prostate-specific antigen : A review of the validation of the most commonly used cancer biomarker. / Hernandez, Javier; Thompson, Ian M.

In: Cancer, Vol. 101, No. 5, 01.09.2004, p. 894-904.

Research output: Contribution to journalArticle

Hernandez, Javier ; Thompson, Ian M. / Prostate-specific antigen : A review of the validation of the most commonly used cancer biomarker. In: Cancer. 2004 ; Vol. 101, No. 5. pp. 894-904.
@article{83804ffd73564dbf962f1e8894142f39,
title = "Prostate-specific antigen: A review of the validation of the most commonly used cancer biomarker",
abstract = "BACKGROUND. The widespread use of prostate-specific antigen (PSA) screening has had a tremendous impact on all aspects of the management of prostate carcinoma. Although PSA-based screening has resulted in a stage migration to more organ-confined tumors at the time of diagnosis, and has been temporally associated with a decrease in prostate carcinoma mortality, PSA screening is imperfect. A recent analysis of results from the Prostate Cancer Prevention Trial (PCPT) has provided insight into the positive predictive value of PSA in the so-called {"}normal{"} range. METHODS. The history of the discovery, initial studies, and subsequent widespread application of PSA screening is reviewed. RESULTS. The application of PSA for screening preceded the development of current prostate biopsy techniques and an upper limit of normal was established without complete disease ascertainment. More recent modifications of PSA-based screening have been adopted clinically without sufficient validation. With current methods, overdiagnosis of clinically unimportant disease almost certainly occurs and high-grade, aggressive disease may not be detected sufficiently early to allow successful treatment. CONCLUSIONS. To the authors' knowledge, the optimal upper limit of normal for PSA for prostate carcinoma screening is unknown. New biomarkers of disease are needed; these must be linked with disease prognosis and must be validated in rigorously designed clinical trials.",
keywords = "Biomarkers, Prostate carcinoma, Prostate-specific antigen (PSA), Screening",
author = "Javier Hernandez and Thompson, {Ian M.}",
year = "2004",
month = "9",
day = "1",
doi = "10.1002/cncr.20480",
language = "English (US)",
volume = "101",
pages = "894--904",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Prostate-specific antigen

T2 - A review of the validation of the most commonly used cancer biomarker

AU - Hernandez, Javier

AU - Thompson, Ian M.

PY - 2004/9/1

Y1 - 2004/9/1

N2 - BACKGROUND. The widespread use of prostate-specific antigen (PSA) screening has had a tremendous impact on all aspects of the management of prostate carcinoma. Although PSA-based screening has resulted in a stage migration to more organ-confined tumors at the time of diagnosis, and has been temporally associated with a decrease in prostate carcinoma mortality, PSA screening is imperfect. A recent analysis of results from the Prostate Cancer Prevention Trial (PCPT) has provided insight into the positive predictive value of PSA in the so-called "normal" range. METHODS. The history of the discovery, initial studies, and subsequent widespread application of PSA screening is reviewed. RESULTS. The application of PSA for screening preceded the development of current prostate biopsy techniques and an upper limit of normal was established without complete disease ascertainment. More recent modifications of PSA-based screening have been adopted clinically without sufficient validation. With current methods, overdiagnosis of clinically unimportant disease almost certainly occurs and high-grade, aggressive disease may not be detected sufficiently early to allow successful treatment. CONCLUSIONS. To the authors' knowledge, the optimal upper limit of normal for PSA for prostate carcinoma screening is unknown. New biomarkers of disease are needed; these must be linked with disease prognosis and must be validated in rigorously designed clinical trials.

AB - BACKGROUND. The widespread use of prostate-specific antigen (PSA) screening has had a tremendous impact on all aspects of the management of prostate carcinoma. Although PSA-based screening has resulted in a stage migration to more organ-confined tumors at the time of diagnosis, and has been temporally associated with a decrease in prostate carcinoma mortality, PSA screening is imperfect. A recent analysis of results from the Prostate Cancer Prevention Trial (PCPT) has provided insight into the positive predictive value of PSA in the so-called "normal" range. METHODS. The history of the discovery, initial studies, and subsequent widespread application of PSA screening is reviewed. RESULTS. The application of PSA for screening preceded the development of current prostate biopsy techniques and an upper limit of normal was established without complete disease ascertainment. More recent modifications of PSA-based screening have been adopted clinically without sufficient validation. With current methods, overdiagnosis of clinically unimportant disease almost certainly occurs and high-grade, aggressive disease may not be detected sufficiently early to allow successful treatment. CONCLUSIONS. To the authors' knowledge, the optimal upper limit of normal for PSA for prostate carcinoma screening is unknown. New biomarkers of disease are needed; these must be linked with disease prognosis and must be validated in rigorously designed clinical trials.

KW - Biomarkers

KW - Prostate carcinoma

KW - Prostate-specific antigen (PSA)

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=4143148652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4143148652&partnerID=8YFLogxK

U2 - 10.1002/cncr.20480

DO - 10.1002/cncr.20480

M3 - Article

C2 - 15329895

AN - SCOPUS:4143148652

VL - 101

SP - 894

EP - 904

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5

ER -